Aytu BioPharma Secures Five-Year Patent Extension for Novel Depression Drug EXXUA Through 2030
Key Insights
Aytu BioPharma announced a five-year patent extension for EXXUA (gepirone) through September 2, 2030, expanding beyond the FDA's new chemical entity exclusivity period.
EXXUA represents the first-in-class selective serotonin 5HT1a receptor (search) agonist approved for major depressive disorder (search) treatment in adults.
The company plans to commercially launch EXXUA in 2025 to address unmet needs for the estimated 21 million Americans affected by major depressive disorder (search).
Aytu BioPharma announced that the U.S. Patent and Trademark Office has granted a five-year extension for the method of use patent (U.S. Patent No. 7,538,116) covering EXXUA (gepirone) extended-release tablets, extending protection through September 2, 2030. The patent extension builds upon the new chemical entity (NCE) exclusivity period previously granted by the FDA for this first-in-class selective serotonin 5HT1a receptor (search) agonist approved for treating major depressive disorder (search) in adults.
Patent Protection Strengthens Market Position
"We are very pleased that the EXXUA patent has been granted this five year extension which adds to the exclusivity beyond that normally provided by the NCE approval," commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma. The company continues discussions with partners regarding potential life cycle management approaches that could extend exclusivity beyond 2030.
The patent extension provides Aytu BioPharma with enhanced intellectual property protection as the company prepares for EXXUA's commercial launch in 2025. Gepirone's designation as a new chemical entity by the FDA underscores its novel mechanism of action in the depression treatment landscape.
Addressing Unmet Medical Needs in Depression
EXXUA is positioned to serve the estimated 21 million Americans affected by major depressive disorder (search). Disbrow emphasized the drug's potential to address significant treatment challenges, stating, "Although progress has been made in depression treatments, challenges like treatment-related sexual dysfunction and weight gain remain significant drawbacks for many MDD (search) therapies."
The selective serotonin 5HT1a receptor (search) agonist mechanism represents a departure from traditional antidepressant approaches. "We believe EXXUA will be a crucial option for doctors treating the millions of patients with MDD (search) in the United States," Disbrow concluded.
Safety Profile and Clinical Considerations
EXXUA carries important safety warnings, including a boxed warning regarding increased risk of suicidal thoughts and behaviors in pediatric and young adult patients observed in short-term antidepressant studies. The drug is not approved for pediatric use and requires careful monitoring for clinical worsening and emergence of suicidal ideation.
Key contraindications include patients with prolonged QTc intervals greater than 450 msec, congenital long QT syndrome, severe liver problems, and concurrent use of strong CYP3A4 inhibitors or monoamine oxidase inhibitors. Healthcare providers must conduct electrocardiogram monitoring and electrolyte testing before and during treatment due to potential QT prolongation risks.
Company Portfolio and Focus
Aytu BioPharma specializes in developing innovative medicines for complex central nervous system diseases. Beyond EXXUA, the company's prescription portfolio includes Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) for attention deficit hyperactivity disorder (search) treatment, along with legacy products including Karbinal ER, Poly-Vi-Flor, and Tri-Vi-Flor.
The company is also exploring EXXUA's potential applications in other psychiatric disorders, though specific development timelines and indications were not disclosed in the announcement.